🔗 Share this article

As the US undertakes historic revisions to its vaccine recommendations, one figure has emerged somewhat surprisingly: Dr. Tracy Beth Høeg, a Danish American sports medicine doctor and public health researcher who initially gained attention by casting doubt on Covid shots in the pandemic and has focused upon potential fatalities after Covid vaccination in her recent time at the FDA.

Proposed Changes to Pediatric Vaccine Program

Agency leaders had intended to announce major changes to the pediatric vaccination calendar in December, bringing the US with Denmark’s immunization schedule, according to reports – a substantial departure that would put the US out of alignment with many the global community with little proof for improved outcomes. This reveal has been delayed until the new year.

In place of the director of the vaccine center, Tracy Beth Høeg is listed to speak at the meeting. She was newly appointed acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to lead the office this calendar year.

Consolidating Power at the FDA

This interim role could signify a closer partnership between the pharmaceutical and vaccine branches as Dr. Høeg and Prasad solidify control at the agency – and it points to a greater focus upon reevaluating long-standing immunizations at the FDA.

The new acting director has frequently advocated for discontinuing specific pediatric immunization guidelines in the US in order to be more like Denmark's approach, a nation with comprehensive healthcare and a citizenry about the size of Wisconsin’s.

To date public appearances, she has persisted in emphasizing on vaccination policy – typically the domain of Prasad, director of the FDA’s vaccine center – rather than medication approval.

Doubts Over Background

The appointee has no obvious track record in pharmaceutical research, approval processes or administrative roles, which has been typical for past leaders of the Center for Biologics Evaluation and Research. She has worked at the FDA as a key advisor to the agency head and CBER since March.

“She doesn’t seem to have the necessary background” for running the CDER, said Jonathan Howard. “She has not conducted a clinical trial. She has no expertise in managing a sizeable institution. She is not an expert in pharmaceutical oversight.”

Former commissioners of the center would “be deeply familiar with laws and regulations and the research of drug development”, said Janet Woodcock. “Clearly, she has not acquired the kind of background that former directors who ran CBER have had.”

CDER has an immense portfolio at the agency, the former commissioner pointed out.

“The public just focuses on the new drug program, but the generic program approves a multitude of generic drugs. There is also a biologic copycat branch, non-prescription drug unit and more, and every single one must be managed,” Woodcock said. “The responsibility you overlook, that is precisely what that I always told people is going to come back to haunt you.”

There is also, a substantial administrative component to the role, which supervises more than 5,000 personnel. “It is a enormous management job, if you perform it correctly,” the former official said.

Official Statement and Contentious Programs

When asked about concerns about Høeg’s fitness for the role and whether this selection represents greater collaboration among FDA leaders on vaccines, a press secretary responded that the “concerns stem from incorrect presumptions”.

“Her experience aligns with the responsibilities of her role,” the spokesperson stated, pointing to the months Dr. Høeg spent guiding the FDA commissioner on “medication safety and approval science, including predictive safety algorithms and vaccine surveillance”.

As the temporary head, Dr. Høeg takes over the agency head's new priority voucher program, a contentious rapid drug-approval program that allegedly worried her predecessors. “How are these drugs being selected for this expedited pathway? Who takes the decisions?” Howard asked. “There is a lot of secrecy going on at the agency right now.”

In general, he remarked, “the Food and Drug Administration looks to be trending towards laxer rules of most medications, with the exception of shots.”

Documented Track Record on Immunizations

Concerning immunizations, Høeg has a more established, if problematic, history, some experts observe. She authored a analysis using unverified crowd-sourced reports to estimate the frequency of myocarditis after Covid immunization. She counseled the state of Florida chief medical officer Joseph Ladapo, who allegedly have changed statistics to imply Covid vaccinations are more dangerous than they are.

Among her “desired changes” for the incoming federal leadership encompassed revising rules for new vaccines and ending “optional” immunizations, she stated following the vote on a podcast. At the FDA, Høeg has allegedly suggested excluding teenage boys from receiving Covid vaccinations.

“She is an complete dogmatist who begins with her conclusions and reverse-engineers to retrofit the data in a highly disingenuous, untruthful manner,” Dr. Howard stated.

Gaining Influence and a “Revenge Tour”

Høeg joined fellow contrarians, {like|